Human Dental Pulp-Derived Stem Cells Promote Locomotor …
By daniellenierenberg
Characterization of isolated human SHEDs and DPSCs for use in transplantation studies. Flow cytometry analysis showed that the SHEDs and DPSCs expressed a set of mesenchymal stem cell (MSC) markers (i.e., CD90, CD73, and CD105), but not endothelial/hematopoietic markers (i.e., CD34, CD45, CD11b/c, and HLA-DR) (Table 1). Like human BMSCs, both the SHEDs and DPSCs exhibited adipogenic, chondrogenic, and osteogenic differentiation as described previously (refs. 16, 17, and data not shown). The majority of SHEDs and DPSCs coexpressed several neural lineage markers: nestin (neural stem cells), doublecortin (DCX; neuronal progenitor cells), III-tubulin (early neuronal cells), NeuN (mature neurons), GFAP (neural stem cells and astrocytes), S-100 (Schwann cells), and A2B5 and CNPase (oligodendrocyte progenitor cells), but not adenomatous polyposis coli (APC) or myelin basic protein (MBP) (mature oligodendrocytes) (Figure 1A and Table 1). This expression profile was confirmed by immunohistochemical analyses (Figure 1B).
Characterization of the SHEDs and DPSCs used for transplantation. (A) Flow cytometry analysis of the neural cell lineage markers expressed in SHEDs. Note that most of the SHEDs and DPSCs coexpressed neural stem and multiple progenitor markers, but not mature oligodendrocytes (APC and MBP). (B) Confocal images showing SHEDs coexpressed nestin, GFAP, and DCX. SHEDs also expressed markers for oligodendrocyte progenitor cells (A2B5 and CNPase), but not for mature oligodendrocytes (APC and MBP). Scale bar: 10 m. (C) Real-time RT-PCR analysis of the expression of neurotrophic factors. Results are expressed as fold increase compared with the level expressed in skin fibroblasts. Data represent the average measurements for each cell type from 3 independent donors. This set of experiments was repeated twice and yielded similar results. Data represent the mean SEM. *P < 0.01 compared with BMSCs and fibroblasts (Fbs).
Flow cytometry of stem cells from humans
Next, we examined the expression of representative neurotrophic factors by real-time PCR. Both the SHEDs and DPSCs expressed glial cellderived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and ciliary neurotrophic factor (CNTF) at more than 3 to 5 times the levels expressed by skin-derived fibroblasts or BMSCs (Figure 1C).
We further characterized the transcriptomes of SHEDs and BMSCs by cDNA microarray analysis. This gene expression analysis revealed a 2.0-fold difference in the expression of 3,318 of 41,078 genes between SHEDs and BMSCs. Of these, 1,718 genes were expressed at higher levels in the SHEDs and 1,593 genes were expressed at lower levels (data not shown). The top 30 genes showing higher expression in the SHEDs were in the following ontology categories: extracellular and cell surface region, cell proliferation, and tissue/embryonic development (Table 2).
Functional gene classification in SHEDs versus BMSCs
SHEDs and DPSCs promoted locomotor recovery after SCI. To compare the neuroregenerative activities of human SHEDs and DPSCs with those of human BMSCs and human skin fibroblasts, we transplanted the cells into the completely transected SCs, as described in Methods, and evaluated locomotion recovery using the Basso, Beattie, Bresnahan locomotor rating scale (BBB scale) (24). Remarkably, the animals that received SHEDs or DPSCs exhibited a significantly higher BBB score during the entire observation period, compared with BMSC-transplanted, fibroblast-transplanted, or PBS-injected control rats (Figure 2A). Importantly, their superior recoveries were evident soon after the operation, during the acute phase of SCI. After the recovery period (5 weeks after the operation), the rats that had received SHEDs were able to move 3 joints of hind limb coordinately and walk without weight support (P < 0.01; Supplemental Videos 1 and 2), while the BMSC- or fibroblast-transplanted rats exhibited only subtle movements of 12 joints. These results demonstrate that the transplantation of SHEDs or DPSCs during the acute phase of SCI significantly improved the recovery of hind limb locomotor function. Since the level of recovery was similar in the SHED- and DPSC-transplanted rats, we focused on the phenotypical examination of SHED-transplanted rats to elucidate how tooth-derived stem cells promoted the regeneration of the completely transected rat SC.
Engrafted SHEDs promote functional recovery of the completely transected SC. (A) Time course of functional recovery of hind limbs after complete transection of the SC. A total of 1 106 SHEDs, DPSCs, BMSCs, or fibroblasts were transplanted into the SCI immediately after transection. Data represent the mean SEM. **P < 0.001, *P < 0.01 compared with SCI models injected with PBS. (BD) Representative images (B and C) and quantification (D) of NF-Mpositive nerve fibers in sagittal sections of a completely transected SC, at 8 weeks after SCI. Dashed lines outline the SC. Insets are magnified images of boxed areas in B and C. (D) Nerve fiber quantification, representing the average of 3 experiments performed under the same conditions. The x axis indicates specific locations along the rostrocaudal axis of the SC (3 mm rostral and caudal to the epicenter), and y axis indicates the percentage of NF-Mpositive fibers compared with that of the sham-operated SCs at the ninth thoracic spinal vertebrate (Th9) level. Data represent the mean SEM. *P < 0.05 compared with SCI models injected with PBS. Scale bars: 100 m and inset 20 m (B) and 50 m (C). Asterisks in B and C indicate the epicenter of the lesion.
SHEDs regenerated the transected corticospinal tract and raphespinal serotonergic axons. To examine whether engrafted SHEDs affect the preservation of neurofilaments, we performed immunohistochemical analyses with an antineurofilament M (NF-M) mAb, 8 weeks after transection. Compared with the PBS-treated control SCs, the SHED-transplanted SCs exhibited greater preservation of NF-positive axons from 3 mm rostral to 3 mm caudal to the transected lesion site (Figure 2, B and C; asterisk indicates epicenter). The percentages of NF-positive axons in the epicenter of the SHED-transplanted and control SCs were 35.8% 13.0% and 8.7% 3.4%, respectively, relative to sham-treated SCs (Figure 2D).
Regeneration of both the corticospinal tract (CST) and the descending serotonergic raphespinal axons is important for the recovery of hind limb locomotor function in rat SCI. We therefore examined whether these axons had extended beyond the epicenter in the SHED-transplanted SCs. The CST axons were traced with the anterograde tracer biotinylated dextran amine (BDA), which was injected into the sensorimotor cortex. The serotonergic raphespinal axons were immunohistochemically detected by a mAb that specifically reacts with serotonin (5-hydroxytryptamine [5-HT]), which is synthesized within the brain stem. We found that both BDA- and 5-HTpositive fibers extended as far as 3 mm caudal to the epicenter in the SHED-transplanted but not the control group (Figures 3 and 4). Furthermore, some BDA- and 5-HTpositive boutons could be seen apposed to neurons in the caudal stump (Figure 3D and Figure 4C), suggesting that the regenerated axons had established new neural connections. Notably, although the number of descending axons extending beyond the epicenter was small, we observed many of them penetrating the scar tissue of the rostral stump (Figure 3A and Figure 4A). The percentages of 5-HTpositive axons of the SHED-transplanted SCs at 1 and 3 mm rostral to the epicenter were 58.9% 3.9% and 78.3% 7.4% relative to sham-treated SC, respectively (Figure 4D). These results demonstrate that the engrafted SHEDs promoted the recovery of hind limb locomotion via the preservation and regeneration of transected axons, even in the microenvironment of the damaged CNS.
View post:
Human Dental Pulp-Derived Stem Cells Promote Locomotor ...
- Bone marrow mesenchymal stem cells modulate miR-202-3p to suppress neuronal apoptosis following spinal cord injury through autophagy activation via... - December 9th, 2024
- Stem Cells Reveal Secret to Beneficial Proteins for mRNA Therapy - An Interview with Neuroscientist Prof. Dr. Antal Ngrdi - Szegedi Tudomnyegyetem - December 9th, 2024
- Much-anticipated human trial aiming to repair spinal cord damage about to begin - ABC News - October 21st, 2024
- The Science Of Health: Are Spinal Cord Injuries Irreversible? Know Science Advances That Can Cure Them In The Future - ABP Live - October 16th, 2023
- Evaluating the Growth Prospects of the Global Nerve Repair & Regeneration Market at a CAGR of 6.5% | Emergen - EIN News - April 21st, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 17th, 2023
- Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx for the Treatment of ALS - Marketscreener.com - February 21st, 2023
- My Back Is All F*cked Up 55-Year-Old Joe Rogan Curses at Worst Jiu-Jitsu for Painful Health Condition - EssentiallySports - February 21st, 2023
- Brain and Spinal Cord Tumors: Hope Through Research - January 3rd, 2023
- 14.3 The Brain and Spinal Cord Anatomy & Physiology - January 3rd, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - January 3rd, 2023
- Spinal cord injury - Diagnosis and treatment - Mayo Clinic - December 25th, 2022
- Spinal Cord Injury: Hope Through Research | National Institute of ... - December 1st, 2022
- Stem cell controversy - Wikipedia - October 13th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 13th, 2022
- The eye and stem cells: the path to treating blindness - October 13th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology - Yahoo Finance - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Horizon Therapeutics plc Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS... - October 13th, 2022
- Physiology, Spinal Cord - StatPearls - NCBI Bookshelf - October 5th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 ... - October 5th, 2022
- Revolutionary Jab that Could Repair Spinal Cord Injuries Developed by Scientists - Good News Network - October 5th, 2022
- How the 'Love Hormone' Oxytocin May Help Heal Heart Muscles - Healthline - October 5th, 2022
- Unlocking the Mysteries of Brain Regeneration Groundbreaking Study Offers New Insight - SciTechDaily - October 5th, 2022
- In Conversation: How to understand chronic pain - Medical News Today - October 5th, 2022
- New drug could cure aggressive brain cancer stopping tumours in their tracks... - The US Sun - September 27th, 2022
- Rehabilitating spinal cord injury and stroke with graphene and gaming - Nanowerk - September 19th, 2022
- Induced Pluripotent Stem Cells Market Reaches at a CAGR of 8.0% in the Forecast Periods [2021-2031] - BioSpace - September 19th, 2022
- Axolotls can regenerate their brains - Big Think - September 19th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the... - September 11th, 2022
- Spinal Muscular Atrophy: Causes and importance of early diagnosis for proactive management - Firstpost - September 11th, 2022
- Increasing Road Accidents and Fall Injuries among Aged Population Primarily Driving Need for Orthopedic Navigation Systems: Fact.MR Analysis - Yahoo... - September 3rd, 2022
- Culture of human nasal olfactory stem cells and their extracellular vesicles as advanced therapy medicinal products - Newswise - August 10th, 2022
- Curious kids: what is inside teeth? - The Conversation - August 10th, 2022
- Human placental mesenchymal stem cells derived exosomes improved functional recovery via attenuating apoptosis and increasing axonal regeneration... - August 2nd, 2022
- How the Regenerative Properties of Glioblastoma Can Be Terminated - Gilmore Health News - August 2nd, 2022
- New TSXV listing looks to address the $3B spinal cord injury treatment market (NRX.V) - FXStreet - July 25th, 2022
- Human iPSC co-culture model to investigate the interaction between microglia and motor neurons | Scientific Reports - Nature.com - July 25th, 2022
- Negligence in treatment of diseases like glioblastoma can be fatal, seminar told - The News International - July 25th, 2022
- What lab-grown cerebral organoids are revealing about the brain - New Scientist - July 25th, 2022
- Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting - Targeted Oncology - July 16th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 16th, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - June 30th, 2022
- This startup wants you to have a personal stem cell stash - Freethink - June 30th, 2022
- Parents of 12-Year-Old Boy Praying for a Miracle, Appealing UK Judge's Decision to Remove Life Support - CBN.com - June 30th, 2022
- The end of Roe v. Wade affects more than just abortion - Vox.com - June 30th, 2022
- Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA (inebilizumab) in Brazil - Business Wire - June 20th, 2022
- Effect of Electrical Stimulation on Spinal Cord Injury: In Vitro and In Vivo Analysis - Newswise - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UK Judge to Decide if 12-Year-Old Will Be Removed from Life Support, Parents Beg for More Time to Heal - CBN.com - June 11th, 2022
- 'This is my life, and I'll try anything to save it': Woman with MS raising funds for treatment - The Brandon Sun - May 29th, 2022
- Racing Thoughts: Quadriplegic Man Drives Race Car With His Brain - Newsy - May 29th, 2022
- Physical therapy for vertigo: Exercises, benefits, and more - Medical News Today - May 29th, 2022
- Researchers find new function performed by almost half of brain cells - Medical News Today - May 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 13th, 2022
- Severe COVID-19 may cause cognitive deficits equivalent to 20 years of aging - Medical News Today - May 13th, 2022
- Stem Cell Magic: 5 Promising Treatments For Major Medical Conditions - Study Finds - April 29th, 2022
- Neural Stem Cell Therapy For Spinal Cord Injury To Tap Into The Potential Of Stem Cells - Optic Flux - April 15th, 2022
- Still Blooming: Sams mission to raise money for spinal cord injury research - 7NEWS - April 15th, 2022
- Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung... - April 15th, 2022
- Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss - Galveston County Daily News - March 22nd, 2022
- COVID-19: Even mild to moderate infection may cause brain anomalies - Medical News Today - March 22nd, 2022
- Scots mum with MS says 50k treatment abroad is 'last hope' of halting disease - Daily Record - January 18th, 2022
- Mending the gap: U of T's Molly Shoichet joins team developing new treatments for spinal cord injuries - News@UofT - January 18th, 2022
- Spinal Cord Injury Information Page | National Institute ... - January 3rd, 2022
- Dancing molecules successfully repair severe spinal cord ... - January 3rd, 2022
- Best 2021 Medical Breakthroughs And Treatments to Beat Cancer, Alzheimer's, Diabetes & More - Good News Network - January 3rd, 2022
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Scientists unravel a gene function that helps the genesis of neurons - Research Matters - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- 2021: The year in review | YaleNews - Yale News - December 23rd, 2021
- Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire - December 10th, 2021
- Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen... - November 8th, 2021
- Akiko Nishiyama Explains the Many Strengths of a Degree in Physiology and Neurobiology - UConn Today - UConn Today - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- 'Rogue' antibodies found in brains of teens with delusions and paranoia after COVID-19 - Livescience.com - October 28th, 2021